| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC (NCT07197580) | Telix Pharmaceuticals (Innovations) Pty Limited | 2026-03-25 |
| Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (NCT07100730) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-11-02 |
| Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain (NCT07197645) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-10-21 |
| [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes (NCT07238322) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-09-22 |
| PSMA PET Combined With MRI for the Detection of PCa (NCT07052214) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-08-18 |
| Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations (NCT06655064) | Telix Pharmaceuticals (Innovations) Pty Limited | 2025-01-30 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study (NCT06750419) | Telix Pharmaceuticals (Innovations) Pty Limited | 2024-11-06 |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) (NCT06520345) | Telix Pharmaceuticals (Innovations) Pty Limited | 2024-07-26 |
| 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients (NCT05847348) | Telix Pharmaceuticals (Innovations) Pty Limited | 2023-07-19 |
| Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma (NCT05861778) | Telix Pharmaceuticals (Innovations) Pty Limited | 2023-06-26 |
| Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors (NCT05868174) | Telix Pharmaceuticals (Innovations) Pty Limited | 2023-05-23 |
| 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (NCT05450744) | Telix Pharmaceuticals (Innovations) Pty Limited | 2023-04-01 |
| External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) (NCT05146973) | Telix Pharmaceuticals (Innovations) Pty Limited | 2022-08-30 |
| 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (NCT04726033) | Telix Pharmaceuticals (Innovations) Pty Limited | 2021-08-04 |
| Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC (NCT04496089) | Telix Pharmaceuticals (Innovations) Pty Limited | 2020-08-01 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study (NCT03849118) | Telix Pharmaceuticals (Innovations) Pty Limited | 2019-08-15 |
| 131I-IPA and Concurrent XRT in Recurrent GBM (NCT03849105) | Telix Pharmaceuticals (Innovations) Pty Limited | 2019-04-09 |